Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date01 Jan 1996 |
榄香烯乳状注射液联合化疗治疗III/IV期非小细胞肺癌的有效性和安全性的上市后临床试验
[Translation] Post-marketing clinical trial on the efficacy and safety of elemene emulsion injection combined with chemotherapy in the treatment of stage III/IV non-small cell lung cancer
1,评价榄香烯乳状注射液联合化疗治疗III/IV期非小细胞肺癌的有效性; 2,评价榄香烯乳状注射液联合化疗治疗III/IV期非小细胞肺癌的安全性。
[Translation] 1. To evaluate the efficacy of elemene emulsion injection combined with chemotherapy in the treatment of stage III/IV non-small cell lung cancer; 2. To evaluate the safety of elemene emulsion injection combined with chemotherapy in the treatment of stage III/IV non-small cell lung cancer.
[Translation] Post-marketing re-evaluation clinical study of elemene emulsion injection/oral emulsion
评价榄香烯乳状注射液/口服乳联合含奥沙利铂的系统化疗方案一线治疗晚期原发性肝癌的有效性和安全性。
[Translation] To evaluate the efficacy and safety of elemene emulsion injection/oral emulsion combined with oxaliplatin-containing systemic chemotherapy as first-line treatment for advanced primary liver cancer.
[Translation] Post-marketing re-evaluation clinical study of elemene emulsion injection/oral emulsion
评价榄香烯乳状注射液/口服乳联合最佳支持治疗晚期原发性肝癌的有效性和安全性。
[Translation] To evaluate the efficacy and safety of elemene emulsion injection/oral emulsion combined with best supportive care for advanced primary liver cancer.
100 Clinical Results associated with Dalianhualijingang Pharmaceutical Co. Ltd.
0 Patents (Medical) associated with Dalianhualijingang Pharmaceutical Co. Ltd.
100 Deals associated with Dalianhualijingang Pharmaceutical Co. Ltd.
100 Translational Medicine associated with Dalianhualijingang Pharmaceutical Co. Ltd.